TP53 and myeloproliferative neoplasm: Additional details from the particular study [25] revealed similar CR/CRi rates between patients who received HMA-Ven upfront or in the relapsed setting, with azacitidine or decitabine, or with or without prior HMA exposure; CR/CRi rates were also not affected by MPN driver mutation status or presence or absence of TP53 (41% vs. 44%), ASXL1 (47% vs. 41%), IDH1/2 (50% vs. 41%), or K/NRAS (20% vs. 46%) mutations.